Idiopathic pulmonary fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a life-debilitating chronic lung disease characterized by progressive scarring of the lung. Patients with IPF suffer from shortness of breath, persistent dry cough, fatigue, and if left untreated, the progressive scarring can lead to the necessity for lung transplantation. Despite advancements in the understanding of the pathophysiology of the disease, treatment options for IPF are limited. Interna Therapeutics has an active anti-IPF program that is based on an MNM-siRNA conjugate targeting a gene of interest. Positive proof of concept was observed in a bleomycin-induced IPF mouse model, and several other candidates are being studied.
